WRF
PTCT icon

Waddell & Reed Financial’s PTC Therapeutics PTCT Stock Holding History

Waddell & Reed Financial’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-116,518
Closed -$5.91M – 479
2020
Q2 		$5.91M Buy
+116,518
New +$5.73M 0.02% 412
2016
Q2 		– Sell
-131,684
Closed -$848K – 612
2016
Q1 		$848K Sell
131,684
-1,722,500
-93% -$29.9M ﹤0.01% 588
2015
Q4 		$60.1M Buy
1,854,184
+61,184
+3% +$1.8M 0.1% 190
2015
Q3 		$47.9M Buy
1,793,000
+521,500
+41% +$22.3M 0.08% 216
2015
Q2 		$61.2M Buy
+1,271,500
New +$74.2M 0.09% 206

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Waddell & Reed Financial's PTCT Position: Q3 2020 in Review

Waddell & Reed Financial sold out of PTC Therapeutics (PTCT) in Q3 2020, closing a stake of 116,518 shares — an estimated $5.91M sold.

Waddell & Reed Financial first reported a position in PTCT in Q2 2015 and held it in 5 quarters. The position peaked at $61.2M in Q2 2015. 197 funds tracked by Wall St. Rank hold PTCT as of Q3 2020.

  • Waddell & Reed Financial reported no remaining PTC Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Waddell & Reed Financial sold 116,518 PTC Therapeutics shares in Q3 2020, an estimated $5.91M.
  • Waddell & Reed Financial first reported a position in PTC Therapeutics in Q2 2015 and held it in 5 quarters.
  • Waddell & Reed Financial's PTC Therapeutics position peaked at $61.2M in Q2 2015.
  • 197 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2020.

Based on Waddell & Reed Financial's 13F filing for Q3 2020, filed 13 Nov 2020.